samedan logo
 
 
spacer
home > ebr > summer 2002 > good news for european bioinformatics - the database right
PUBLICATIONS
European BioPharmaceutical Review

Good News for European Bioinformatics - The Database Right

Scientific research is reliant upon databases of ever-increasing size and sophistication. It is vital for any business which exploits such databases - whether as an owner or as a licensee - to understand the way in which the law protects them. In Europe, companies creating databases can benefit from a special form of protection called 'database right' (sometimes called 'sui generis right'). This right is distinct from, and additional to, any copyright or other intellectual property right which may subsist in the database and its contents. Its focus is on protecting investment in databases. Database right is not available to companies based in countries outside Europe and which have not agreed to reciprocal protection for databases. The US is an important example of a country where database right is currently not available.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Daniel Pavin, a Solicitor Specialising in Intellectual Property

and Information Technology Law with Taylor Joynson Garrett
Daniel Pavin is a Solicitor specialising in intellectual property and information technology law. Daniel advises a wide range of clients, and has a particular focus on clients in the pharmaceutical, biotechnology and information technology sectors. He has a Diploma in Intellectual Property Law and Practice from Bristol University, UK.
Daniel has a degree from Cambridge University in Computer Science and Physics and worked as a Computer Programmer before qualifying as a Solicitor.

spacer
Daniel Pavin
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

EuroBiopartnering 2008

7-9 October 2008, Paris, France

EuroBiOpartnering 2008 gives you the unique opportunity to meet the relevant decision makers and opinion leaders from the international biotech community and offers you 3 days of partnering opportunities including one-to-one meetings, company presentations and further networking activities…
More info >>

 
News and Press Releases

Azopharma Product Development Group, Inc

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement